期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

冠心病合并2型糖尿病患者发生阿司匹林抵抗的研究 被引量：1

The Study of Aspirin Resistance in Patients of Coronary Heart Disease with Type 2 Diabetes
下载PDF
导出
摘要 目的:探讨冠心病(CHD)合并2型糖尿病(DM)患者的阿司匹林抵抗(AR)现象。方法:226例CHD合并2型DM患者,服用阿司匹林100mg/d×7d后,分别用二磷酸腺苷(ADP)、花生四烯酸(AA)诱导检测血小板聚集率。分析各组间临床特征、血小板活化指标的差异。结果:226例患者中AR的发生率为5.31%,阿司匹林半抵抗的发生率为31.4%;与阿司匹林敏感组相比,AR的临床特征为高密度脂蛋白减低和高甘油三酯患者居多。结论:在服用常规剂量阿司匹林的CHD合并2型DM患者中AR的发生率为5.31%,合并脂代谢异常的DM患者易发生AR或阿司匹林半抵抗。 Objective：To investigate the aspirin resistance in patients of coronary heart disease with type 2 diabetes. Methods：226 patients of coronary heart disease with type 2 diabetes, after taking aspirin 100mg/d×7d, adenosine diphosphate （ADP）, arachidonic acid （AA） induced platelet aggregation were detected respectively. The differences of clinical characteristics, the Indicators of platelet activation between groups were analysised. Results：The incidence of aspirin resistance in 226 cases patients was 5.31%, the incidence of aspirin-semi-resistance was halfo31.4%.Compared with the aspirin-sensitive group, the clinical characteristics of aspirin resistance were mainly in reduced high-density lipoprotein and high triglycerides in patients. Conclusions：The incidence of aspirin resistance is 5.31% in patients with coronary heart disease complicationg with type 2 diabetes who take regular doses of aspirin, diabetic patients combined with dyslipidemia are Susceptible for aspirin resistance or aspirin-semi-resistant.
作者 王志鹏 刘宝娟 邢冉 冯丽园 杜健 赵铁夫 宁杏敏 谷新梅
机构地区 北京市昌平区沙河医院心内科 首都医科大学附属安贞医院心外科
出处 《中国医药导刊》 2011年第2期206-207,共2页 Chinese Journal of Medicinal Guide
关键词 2型糖尿病 阿司匹林抵抗 血小板聚集率 冠心病 Type 2 diabetes Aspirin resistance Platelet aggregation Coronary heart disease
分类号 R541.4 [医药卫生—心血管疾病] R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献6

  • 1李慧娟,成兴波.2型糖尿病患者的阿司匹林抵抗现象[J].苏州大学学报（医学版）,2007,27(3):446-448. 被引量：13
  • 2Sacco M,Pellegrini F,Roncaglioni MCet al.Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients:results of the Primary Prevention Project (PPP)trial. Diabetes Care . 2003
  • 3Gum P A,Kottke-Marchant K,Poggio E D,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease. The American Journal of Cardiology . 2001
  • 4Pappas J M,Westengard J C,Bull B S.Population variability in the effect of aspirin on platelet function: implications for clinical trials and therapy. Archives of Pathology and Laboratory Medicine . 1994
  • 5Morrow J D.The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metabolism Reviews . 2000
  • 6Nathan DM.Long-term complications of diabetes mellitus. New England Journal of Medicine, The . 1993

二级参考文献7

  • 1Nathan DM.Long-term complications of diabetes mellitus[J].N Engl J Med,1993,328(23):1676-1685.
  • 2Gum P A,Kottke-Marchant K,Poggio E D,et al.Profile and prevalence of aspirin resistance in patientswith cardiovascular disease[J].Am J Cardiol,2001,88(3):230-235.
  • 3Pappas J M,Westengard J C,Bull B S.Population variability in the effect of aspirin on platelet function:implications for clinical trials and therapy[J].Arch Pathol Lab Med,1994,118(8):801-804.
  • 4Sacco M,Pellegrini F,Roncaglioni MC,et al.PPP Collaborative Group.Primary prevention of cardiovascular events with low-dose aspirin and Vitamin E in type 2 diabetic patients:results of the Primary Prevention Project (PPP)trial[J].Diabetes Care,2003,26(12):3264-3272.
  • 5Fateh-Moghadam S,Plockinger U,Cabeza N,et al.Prevalence of aspirin resistance in patients with type 2diabetes[J].Acta Diabetol,2005,42(2):99-103.
  • 6Mo rrow J D.The isoprostanes:their quantification as an index of oxidant stress status in vivo[J].Drug Metab Rev,2000,32(3-4):377-385.
  • 7cezary watala,Justyna Pluta,Jacek Golanski,et al.Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin[J].J Mol Med,2005,83(2):148-158.

共引文献12

同被引文献11

  • 1Grinstein J,Cannon CP. Aspirin resistance: current status and role of tailored therapy [J].Clin Cardiol, 2012,35 ( 11 ) : 673- 681.
  • 2Di Minno G, Lupoli R,Palmieri NM, et al. Aspirin resistance, platelet turnover,and diabetic angiopathy: a 2011 update[J]. Thromb Res,2012,129(3) :341-344.
  • 3Qaseem A,Fihn SD, Williams S, et al. Diagnosis of stable is- chemic heart disease., summary of a clinical practice guideline from the American College of Physicians/Ameriean College of Cardiology Foundation/Ameriean Heart Association/Ameri- can Association for Thoracic Surgery/Preventive Cardiovascu- lar Nurses Association/Society of Thoracic Surgeons[J]. Ann Intern Med,2012,157(10) :729-734.
  • 4Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus[J].Diabetes Care, 2003,26 (11) :3160-3167.
  • 5Lev EI, Patel RT, Maresh KJ, et al. Aspirin and elopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance[J].J Am CollCardiol,2006,47(1) :27-33.
  • 6Li J,Song M, Jian Z, et al. Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence [J].J Atheroscler Thromb,2014,21 (3) :239-247.
  • 7Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is as- sociated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2010, 95(6) :2897 2901.
  • 8Poulsen TS,Jorgensen B,Korsholm L, et al. Prevalence of as pirin resistance in patients with an evolving acute myocardial infarction[J]. Thromb Res, 2007,119 (5) .. 555-562.
  • 9Spranger M, Aspey BS, Harrison MJ. Sex difference in an tithrombotic effect of aspirin[J]. Stroke, 1989,20 ( 1 ) : 34 37.
  • 10Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-respon siveness as measured by PFA-100 in patients with coronary artery disease[J]. Thromb Res, 2002,108 ( 1 ) : 37-42.

引证文献1

二级引证文献12

中国医药导刊
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部